L 696986

Drug Profile

L 696986

Latest Information Update: 21 Jan 1997

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antiglaucomas; Neuroprotectants; Nootropics
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alzheimer's disease; Glaucoma

Most Recent Events

  • 21 Jan 1997 No-Development-Reported for Alzheimer's disease in USA (Unknown route)
  • 21 Jan 1997 No-Development-Reported for Glaucoma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top